Профиль компании · Healthcare

Merck KGaA

MRK · XETRA
Отрасль
Life Science Tools
Биржа
XETRA
Страна / Регион
Germany
Сотрудники
59 077
Текущая цена
141.75
В реальном времени · 27 июля 2026 г.
Цена покупки
≤ €95
Вход с запасом прочности
Балл роста Baillie
49/100
Слабоватый
Внутренняя стоимость · три уровня Текущая цена €141.75 Онлайн · В пределах справедливого диапазона внутренней стоимости

Сводный диапазон оценки · консервативный €90–€95 / справедливый €119–€161 / оптимистичный €180–€195. При €141.75, В пределах справедливого диапазона внутренней стоимости.

На момент публикации €133.05 (19 июня 2026 г.)

Капитализация60,5 млрд €
Выручка (TTM)20,96 млрд €
EBITDA5,67 млрд €
Чистая маржа12,08 %
ROE8,53 %
P/E (TTM)23,87
Прогнозный P/E20,41
PEG2,76
Прибыль на акцию5,83 €
Дивидендная доходность1,58 %
Диапазон за 52 недели98,72 € – 148,65 €

Данные EODHD, показаны в валюте отчётности; только для справки, не является инвестиционной рекомендацией.

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary o

История

Merck KGaA traces its roots to 1668, when Friedrich Jacob Merck acquired the Engel-Apotheke in Darmstadt, described as the historic core of the world's oldest pharmaceutical and chemical company. The modern listed company dates from 1995: it was recorded as a KGaA in July 1995 and first listed on October 20, 1995, with 39,999,999 shares issued at DM 54.00 (€27.61) on Frankfurt/Xetra, and entered the DAX in 2007. Recent corporate moves include the SpringWorks acquisition (equity value about $3.9 billion, enterprise value $3.4 billion), signed in April 2025 and closed on July 1, 2025; the acquisition of JSR Life Sciences' chromatography business, announced in October 2025 and closed on March 31, 2026 and folded into Process Solutions; the sale of Surface Solutions in 2025; and the September 2025 appointment of Kai Beckmann to succeed Belén Garijo as CEO from May 1, 2026.

Положение в отрасли

Merck KGaA is a diversified science and technology group spanning three segments — Healthcare (prescription drugs and biopharmaceuticals), Life Science (lab and bioprocessing tools, consumables, process materials and services) and Electronics (semiconductor and display materials) — with €21.1 billion of 2025 net sales, about 59,077 employees and a market capitalization of roughly €58.1 billion. In Life Science it competes against Danaher, Thermo Fisher and Sartorius, with its 2025 Life Science EBITDA pre of €3.08 billion at a 35.8% margin; in Electronics it competes with Entegris, DuPont's electronics businesses, Tokyo Ohka, Shin-Etsu and JSR; and in Healthcare, UCB is a comparison point. In the United States and Canada the group operates under the EMD Serono, MilliporeSigma and EMD Electronics names, reflecting a trademark separation from the unrelated U.S. Merck & Co.

49/100 Держать Merck KGaA: диверсифицированная научная платформа в переходной фазе Merck KGaA, Дармштадт, — немецкая научно-технологическая группа под семейным контролем, чьи продажи 2025 года в размере €21.1 миллиардов формируются тремя очень разными двигателями: Healthcare с патентной уязвимостью, качественной франшизой инструментов Life Science и бизнесом Electronics в материалах для полупроводников. В 2026 году акция остается полем перетягивания каната: известный патентный обрыв Mavenclad в США тянет Healthcare вниз, тогда как Process Solutions растет органически почти на 10%, а Electronics опирается на спрос ИИ на передовые техпроцессы; после майского отскока до €133.05 акции торгуются около 15.9 раза EPS pre 2025 года и дают 3.5% доходности свободного денежного потока. Рейтинг Держать: действительно сильные двигатели Life Science и материалов для полупроводников компенсируют Healthcare с поврежденной репутацией, но постоянный дисконт корпоративного управления KGaA и лишь справедливая оценка ограничивают потенциал роста. Merck KGaA, Дармштадт, ГерманияMRK · XETRALife Science Tools19 июня 2026 г.